First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study

By afschroeder • November 1, 2025

Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando N, Zavodovskaya M, Jürgensmeier JM, Chisamore M, Cho BC. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2025 Oct 29:S1556-0864(25)02890-4. doi: 10.1016/j.jtho.2025.10.016. Epub ahead of print. PMID: 41173143.

Tags: antibody-drug conjugate, Hematology/Oncology, metastatic, Non-small cell lung cancer, Publications, Sacituzumab govitecan, Trop-2

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]